Abstract
This study evaluates the prognostic value of MAGE-A3 expression in 28 diffuse large B-cell lymphoma (DLBCL) patients. A significant association was observed between MAGE-A3 expressions, assessed by quantitative real-time RT-polymerase chain reaction (PCR), with advanced stages of disease (P < 0.05). Elevated serum lactate dehydrogenase (LDH) levels and International Prognostic Index (IPI) score were significantly higher in MAGE-A3-positive patients (P = 0.025 and P = 0.004, respectively). Expression of MAGE-A3 was associated with poor response to treatment and a significantly shorter overall survival (P < 0.001). Our data address new information in the association of MAGE-A3 expression and poor prognosis in DLBCL patients.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antigens, Neoplasm / genetics*
-
Antigens, Neoplasm / metabolism
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Blotting, Western
-
Female
-
Gene Expression Regulation, Neoplastic*
-
Humans
-
L-Lactate Dehydrogenase / blood
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Large B-Cell, Diffuse / genetics*
-
Lymphoma, Large B-Cell, Diffuse / metabolism
-
Male
-
Middle Aged
-
Neoplasm Proteins / genetics*
-
Neoplasm Proteins / metabolism
-
Neoplasm Staging
-
Prognosis
-
Reverse Transcriptase Polymerase Chain Reaction
-
Survival Analysis
-
Time Factors
-
Treatment Outcome
-
Young Adult
Substances
-
Antigens, Neoplasm
-
MAGEA3 protein, human
-
Neoplasm Proteins
-
L-Lactate Dehydrogenase